Related Experiment Video
Updated: Nov 8, 2025
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
973
miR-335-5p aggravates type 2 diabetes by inhibiting SLC2A4 expression
1Department of Cardiology, Hubei Third People's Hospital Affiliated to Jianghan University, Wuhan, 430300, Hubei, China.
Biochemical and Biophysical Research Communications
|April 26, 2021
Summary
MicroRNA-335-5p (miR-335-5p) dysregulation impacts type 2 diabetes (T2D). Targeting miR-335-5p and solute carrier family 2 member 4 (SLC2A4) may offer new T2D therapies.
Area of Science:
- Endocrinology and Metabolism
- Molecular Biology
- Genetics
Background:
- Type 2 diabetes (T2D) is a global health crisis affecting 500 million people.
- Dysregulation of miR-335-5p and SLC2A4 is linked to T2D, but mechanisms remain elusive.
Purpose of the Study:
- To investigate the role of the miR-335-5p-SLC2A4 axis in T2D pathogenesis.
- To explore potential therapeutic targets for T2D.
Main Methods:
- Real-Time quantitative PCR (RT-qPCR) to measure miR-335-5p and SLC2A4 levels.
- Luciferase assay to confirm the interaction between miR-335-5p and SLC2A4.
- Cell proliferation (CCK8, BrdU) and apoptosis (caspase-3) assays in glucose-treated pancreatic cells.
Main Results:
- Increased miR-335-5p and decreased SLC2A4 expression were found in T2D blood samples and pancreatic cells.
- miR-335-5p mimic reduced proliferation and increased apoptosis; SLC2A4 overexpression had opposite effects.
- miR-335-5p directly inhibited SLC2A4 expression and pancreatic cell growth.
Conclusions:
- The miR-335-5p targeting of SLC2A4 impairs pancreatic cell growth by reducing proliferation and increasing apoptosis.
- miR-335-5p and SLC2A4 represent promising therapeutic targets for T2D treatment.
More Related Videos
12:33A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
65.7K
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
1.7K
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
4.1K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
323
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
323
01:22Diabetes Mellitus: Type 2 and Gestational
3.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.7K
01:24Glucagon-like Receptor Agonists
519
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
519
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
400
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
400
01:58Cell Specific Gene Expression
14.4K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
14.4K